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Phosphorylation by IKKε/TBK1 as a
Case Study
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Unit of Molecular Signal Transduction in Inflammation, Department of Biomedical Molecular Biology, VIB-UGent Center for
Inflammation Research, Ghent University, Ghent, Belgium
CYLD is a deubiquitinating enzyme that plays a crucial role in immunity and inflammation
as a negative regulator of NF-κB transcription factor and JNK kinase signaling. Defects
in either of these pathways contribute to the progression of numerous inflammatory
and autoimmune disorders. Therefore, we set out to unravel molecular mechanisms
that control CYLD activity in the context of T cell receptor (TCR) signaling. More
specifically, we focused on CYLD phosphorylation at Ser418, which can be detected
upon immunoblotting of cell extracts with phospho(Ser418)-CYLD specific antibodies.
Jurkat T cells stimulated with either anti-CD3/anti-CD28 or PMA/Ionomycin (to mimic
TCR signaling) were used as a model system. The role of specific kinases was analyzed
using pharmacological as well as genetic approaches. Our initial data indicated that
CYLD is directly phosphorylated by the noncanonical IκB kinases (IKKs) IKKε and
TANK Binding Kinase 1 (TBK1) at Ser418 upon TCR stimulation. Treatment with
MRT67307, a small compound inhibitor for IKKε and TBK1, inhibited TCR-induced CYLD
phosphorylation. However, the phospho(Ser418)-CYLD immunoreactive band was still
present in CRISPR/Cas9 generated IKKε/TBK1 double knockout cell lines, where it
could still be prevented by MRT67307, indicating that the initially observed inhibitory
effect of MRT67307 on TCR-induced CYLD phosphorylation is IKKε/TBK1-independent.
Most surprisingly, the phospho(Ser418)-CYLD immunoreactive band was still detectable
upon immunoblotting of cell extracts obtained from CYLD deficient cells. These data
demonstrate the non-specificity of MRT67307 and phospho(Ser418)-CYLD specific
antibodies, implying that previously published results based on these tools may also
have led to wrong conclusions. We therefore advise to use genetic knockout studies
or alternative approaches for a better validation of antibodies and small compound
inhibitors. Interestingly, immunoprecipitation with the phospho(Ser418)-CYLD antibody,
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followed by immunoblotting with anti-CYLD, revealed that CYLD is phosphorylated
by IKKε/TBK1 at Ser418 upon T cell stimulation, but that its direct detection with
the phospho(Ser418)-CYLD-specific antibody in a western blot is masked by another
inducible protein of the same size that is recognized by the same antibody.
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INTRODUCTION
Cylindromatosis (CYLD) is a deubiquitinating enzyme that
was originally identified as a tumor suppressor in familial
cylindromatosis, but has since then also been implicated in
other cancer types (Bignell et al., 2000; Massoumi, 2011).
The majority of CYLD mutations and truncations found in
patients negatively affect its expression or deubiquitinase activity
(Massoumi, 2011). Next to its tumor suppressor function CYLD
is also a key regulator of immunity and inflammation, which is
demonstrated inmultiple CYLD geneticmousemodels (reviewed
in Lork et al., 2017). For example, CYLD knockout mice show
defective T cell development and T cells from these mice are
hyperresponsive to T cell receptor (TCR)-induced activation
and are hyper-proliferative. This hyperresponsive phenotype in
CYLD-deficient mice is associated with autoimmune responses
and bowel inflammation (Reiley et al., 2006; Zhang et al., 2006).
In humans, single nucleotide polymorphisms in the CYLD gene
have been associated with inflammatory bowel disease (Cleynen
et al., 2014). CYLD is a deubiquitinase capable of cleaving K63-
linked as well as M1-linked polyubiquitin chains from target
proteins (Komander et al., 2009; Ritorto et al., 2014). CYLD
negatively regulates nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) signaling by removing polyubiquitin
chains from specific target proteins including NF-κB essential
modifier (NEMO), TNF receptor associated factor (TRAF) 2
and TRAF6, and Transforming growth factor beta-activated
kinase 1 (TAK1) (Brummelkamp et al., 2003; Kovalenko et al.,
2003; Trompouki et al., 2003; Yoshida et al., 2005; Reiley et al.,
2007). In addition, CYLD was shown to negatively affect c-
Jun N-terminal kinase (JNK) and p38 mitogen-activated protein
kinase (MAPK) signaling pathways, which impacts immune
cell function, activation and homeostasis (Yoshida et al., 2005;
Zhang et al., 2006; Reiley et al., 2007). Lack of functional
CYLD leads to constitutively active downstream NF-κB and
MAPK signaling (Reiley et al., 2005; Zhang et al., 2006).
Given the importance of CYLD in inflammation and cancer,
a better understanding of molecular mechanisms regulating
CYLD activity is of considerable interest. CYLD is constitutively
expressed in most cell types (Uhlen et al., 2015), suggesting an
important role for posttranslational modifications in regulating
CYLD activity. Inhibitor of nuclear factor kappa-B kinase
(IKK) β- and NEMO-dependent phosphorylation of CYLD
on multiple residues within a serine cluster between amino
acids 418 and 444 was shown upon stimulation with tumor
necrosis factor (TNF), lipopolysaccharide (LPS) and mitogens
(Reiley et al., 2005). Other work shows that CYLD can be
phosphorylated upon overexpression of the IKK-related kinase
IKKε, facilitating IKKε-driven cellular transformation (Hutti
et al., 2009).
The serine/threonine kinase IKKε and its homolog TANK
binding kinase 1 (TBK1) are referred to as non-canonical IKK
kinases as they are closely related to the canonical IKKα and
IKKβ, sharing 33% sequence identity within their catalytic kinase
domain (Peters et al., 2000; Tojima et al., 2000). IKKε and
TBK1 have been intensively studied in the context of type
I interferon (IFN) induction in response to viral infection
and various pattern recognition receptors, but have also been
implicated in the regulation of a number of other processes
including autophagy, metabolic regulation and oncogenesis
(Shen and Hahn, 2011; Verhelst et al., 2013; Brinkman et al.,
2014; Oakes et al., 2017). IKKε/TBK1-mediated type I IFN
induction is due to their ability to phosphorylate IFN regulatory
factor (IRF) 3 and 7 transcription factors (Fitzgerald et al.,
2003; Sharma et al., 2003; Hemmi et al., 2004). Additionally
IKKε and TBK1 have been described as NF-κB modulators
by phosphorylating IκBα on one of the two critical serines
involved in triggering its degradation (Shimada et al., 1999;
Bonnard et al., 2000; Peters et al., 2000). Even though TBK1 and
IKKε seem to have indistinguishable activities in the activation
of IRF3 and IRF7, they do not seem to be fully redundant
as they have differential expression patterns and substrate
specificities (Fitzgerald et al., 2003; Yu et al., 2012). TBK1 is
expressed ubiquitously, while IKKε expression is restricted to
particular tissues including the lymphoid tissue, peripheral blood
lymphocytes and the pancreas (Shimada et al., 1999; Tojima
et al., 2000). TBK1 knockout mice are embryonically lethal and
die on embryonic day 14.5 due to massive liver degeneration
and apoptosis (Bonnard et al., 2000), while IKKε-deficient mice
are viable (Hemmi et al., 2004). TBK1 and IKKε were shown
to be activated upon TCR stimulation (Peters et al., 2000;
Tojima et al., 2000), but their role in TCR signaling is largely
unknown.
We set out to analyze if the noncanonical kinases IKKε and
TBK1 regulate TCR-mediated signaling by phosphorylating the
deubiquitinase CYLD at Ser418 in Jurkat T cells. Phosphorylation
of CYLD at Ser418 was detected upon immunoblotting of cell
extracts using phospho(Ser418)-CYLD-specific antibodies. The
role of IKKε and TBK1 was assessed using the small compound
inhibitor MRT67307 as well as by IKKε/TBK1 double knockout
cell lines generated via CRISPR/Cas9. Our data demonstrate that
TCR stimulation leads to the phosphorylation of an unknown
protein, which is distinct from CYLD but detectable using
the phospho(Ser418)-CYLD antibody. Moreover, we show that
phosphorylation of this protein can be inhibited by MRT67307
independent of its IKKε and TBK1 inhibitory activity.
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MATERIALS AND METHODS
Cells, Stimulation, Transfection
Jurkat T cells were cultured in Roswell Park Memorial Institute
(RPMI) supplemented with 10% FCS, 1mM sodium pyruvate,
2mM L-glutamine and HEK 293T cells were maintained under
standard culturing conditions in Dulbecco’s Modified Eagle
Medium (DMEM) from Gibco, supplemented with 10% FCS,
1mM sodium pyruvate, 2mM L-glutamine. HEK 293T cells were
transfected with the indicated plasmids using calcium phosphate
and incubated for 24 h at 37◦C/5% CO2 before further use.
IKKε and TBK1 plasmids were a gift from Prof. Alain Chariot
(University of Liege, Belgium). The CYLD S418A cDNA was a
gift from Jessica Hutti, and was recloned into pCAGGS-E-CYLD
(BCCM/GeneCorner plasmid collection; LMBP06613).
IKKε knockout mice were a gift from Prof. Alain Chariot. For
isolation of primary cells, spleens were collected from wild-type
or IKKε deficient mice. Spleens were injected with 5ml PBS +
0.5% BSA using a 25 g needle. Spleens as well as washed out cells
were passed over a 100µm cell strainer, which was further rinsed
with 5ml PBS + 0.5% BSA. Cells were spun for 8min at 1300
rpm at 4◦C and supernatant was removed. Red blood cells were
lysed in 1.7ml ACK buffer per spleen at room temperature for
4min. 5ml PBS + 0.5% BSA per spleen were added and cells
were passed over a 40µm cell strainer and the cell strainer was
rinsed with 1ml PBS + 0.5% BSA. Cells were spun for 8min
at 1,300 rpm at 4◦C and the supernatant was removed. The
cell pellets were resuspended in 2ml IMDM supplemented with
5% FCS, β-mercaptoethanol, 20 U/ml penicillin and 20µg/ml
streptomycin per spleen. For CD4+ T cells isolation the CD4+ T
cell Isolation Kit II protocol (Miltenyi Biotec) was used according
to the manufacturer’s instructions. Cells were stimulated with
different stimuli and inhibitors at the indicated concentrations
(Table 1).
Cell Lysis and Immunoprecipitation
Jurkat T cells or primary CD4+ T cells were lysed in Lysis
buffer (50mM Tris HCl, pH 7.4, 150mMNaCl, 1mM EDTA, 1%
Triton) supplemented with protease and phosphatase inhibitors.
Lysates were cleared by centrifugation for 15min at 14,000
rpm at 4◦C. Protein concentration was measured by Bradford
protein assay (Bio-Rad). 5x Laemmli buffer (250mM Tris-HCl
TABLE 1 | Stimuli and inhibitors used.
Concentration Cat # Supplier
STIMULI
PMA 200 ng/ml P8139 Sigma
Ionomycin 1µM CALB407952 Merck millipore
Anti-CD3 10µg/ml 553057 BD pharmingen
Anti-CD28 10µg/ml 553294 BD pharmingen
TNF 1,000 U/ml – VIB protein service facility
INHIBITORS
MRT67307 1–10µM HY-13018 MedChemtronica
TPCA1 5µM 2559 Tocris biosciences
pH 8, 10% SDS, 50% glycerol, 0.005% bromophenol blue,
25% β-mercaptoethanol) was added to protein lysates and
equal amounts of protein were subjected to immunoblotting.
For immunoprecipitation, cell lysates were incubated overnight
rotating with specific primary antibodies at 4◦C. Then 35 µl of
Dynabeads R© Protein G (Invitrogen) were added and incubated
rotating for 30min at room temperature (RT). Beads were
washed three times with Lysis buffer. Immune complexes were
removed from the beads by boiling for 10min at 90◦C in 1x
Laemmli buffer and subjected to immunoblotting. For total
lysates HEK 293T cells were directly lysed in 1x Laemmli
buffer (50mM Tris-HCl pH 8, 2% SDS, 10% glycerol, 0.001%
bromophenol blue, 5% β-mercaptoethanol).
Immunoblotting
Protein samples were resolved by 8 or 10% SDS-PAGE and
proteins were then transferred to 0.45µm protean nitrocellulose
membranes (Whatman) or Immobilon-FL transfer membranes
(Millipore). The membranes were blocked in 5% milk powder in
TBS/0.2% Tween 20 (TBST) for 1 h at room temperature (RT)
and probed with specific primary antibodies overnight at 4◦C in
5% milk powder in TBST or 5% BSA in TBST. All antibodies
used are listed in Table 2. Membranes were washed three times
in TBST and then incubated with HRP-conjugated secondary
antibodies (GE healthcare) in 5% milk powder in TBST or 5%
BSA in TBST for 1h at RT. Membranes were washed 3 times in
TBST and proteins were detected using the Western Lightning
ECL detection system (Perkin Elmer Life Sciences) according to
the manufacturer’s instructions.
In Vitro Kinase Assay
250 ng recombinant His-CYLD (#64-0010-050, Ubiquigent) and
35, 70, or 140 ng GST-IKKε (#31177, Active Motif) or GST-
TBK1 (#66-0016-050, Ubiquigent) were incubated with 0.6mM
ATP-Mg (#A9187, Sigma) in kinase buffer (20mM Tris-HCl
pH7.5, 10mM MgCl2, 0.1mM sodiumorthovanadate, 5mM
β-glycerophosphate, 2mM DTT) for 30min at 30◦C under
constant rotation at 550 rpm. Reactions were stopped by adding
5x Laemmli buffer and analyzed by immunoblotting.
Engineering of Knockout Cells by
CRISPR/Cas9
Knockout cell lines were generated using CRISPR/Cas9
technology as described previously (Ran et al., 2013). Briefly,
guide RNAs were designed using the design tool provided
by MIT (http://crispr.mit.edu/) and are listed in Table 3.
Oligonucleotides (oligos) coding for the guide sequence
were extended with CACC in the beginning of the top oligo
and CAAA in the end of the bottom oligo. The oligos were
phosphorylated and annealed by incubating 1 µl of each oligo
(100µM stock), 1 µl 10x T4 ligation buffer (M1804, Promega)
and 1 µl T4 polynucleotide kinase (M4101, Promega) in a
total volume of 10 µl in a thermocycler using the following
parameters: 37◦C for 30min, 95◦C for 5min, ramp down to
25◦C at 5◦C/min (=0.1◦C/s). The phosphorylated and annealed
oligos were diluted 1:200 in ddH2O. Oligos were then cloned
into pSpCas9(BB)-2A-GFP (48138, Addgene). The reaction
Frontiers in Cell and Developmental Biology | www.frontiersin.org 3 April 2018 | Volume 6 | Article 40
Lork et al. TCR-Induced CYLD Phosphorylation
TABLE 2 | List of antibodies used.
MP/BSA Dilution Cat # Supplier
P-CYLD BSA 1:1,000 4500 Cell signaling technology
CYLD MP 1:500 sc-74435 Santa Cruz
P-IKKε BSA 1:1,000 8766 Cell signaling technology
IKKε MP 1: 1,000 ab7891 Abcam
P-TBK1 BSA 1: 1,000 5483 Cell signaling technology
TBK1 MP 1: 1,000 3013 Cell signaling technology
P-JNK BSA 1: 1,000 4668 Cell signaling technology
JNK MP 1: 1,000 sc-571 Santa Cruz
P-IkBa BSA 1: 1,000 9246 Cell signaling technology
Actin MP 1:10,000 MP 6472J MP biomedicals
Tubulin MP 1:1,000 T4026 Sigma
E MP 1:2,500 ab66152 Abcam
Myc MP 1:3,000 IRC PEP core
Flag MP 1:1,000 F-3165 Sigma
HA MP 1:1,000 MMS-101R-B Babco
anti-mouse
IgG HRP
MP 1:3,000 NA931-1ML Akta
anti-rabbit
IgG HRP
MP 1:3,000 NA934V GEAkta
anti-goat IgG
HRP
MP 1:3,000 sc-2020 Santa Cruz
MP, Milk Powder.
mix contained 100 ng pSpCas9(BB)-2A-GFP, 2 µl oligo, 2 µl
10x Tango buffer (Fermentas), 0.5mM DTT, 0.5mM ATP, 1
µl FastDigest BbsI (FD1014, Fermentas) and 0.5 µl T4 ligase
(M1804, Promega) in a total volume of 20 µl. The reaction
was incubated for 6 cycles: 5min at 37◦C followed by 5min
at 21◦C. Plasmids were transformed into DH5α competent E.
coli. Plasmid DNA was extracted using the PureLink R© Quick
Plasmid Miniprep Kit (K210010, Invitrogen) according to the
manufacturer’s instructions and the sequences were verified by
Sequencing from the U6 promoter using the U6-Fwd primer
(GAGGGCCTATTTCCCATGATTCC) to check that the 20
nt guide sequence is inserted between the U6 promoter and
the remainder of the sgRNA scaffold. The plasmids (2 µg)
were transfected into 2 × 106 Jurkat T cells using Amaxa cell
line nucleofector kit V (VCA-1003, Lonza) using program
X5 according to the manufacturer’s instructions. Three days
after transfection GFP positive single cells were sorted into
96 well plates using a BD FACS ARIA III (BD Bioscience).
Single cell clones were expanded and knockout was confirmed
on protein level by immunoblotting and on genomic level by
amplification of the region of interest followed by sequencing.
For this, genomic DNA was extracted using QuickExtract
DNA Extraction Solution (QE09050, Epicenter) according
to the manufacturer’s instructions and the region of interest
was amplified using the primers indicated in Table 3 with the
KAPA HiFi HotStart Readymix (KK2602, kapa biosystems)
according to the manufacturer’s instructions. PCR products
were purified using CleanPCR beads (CPCR-0050, Cleanna)
according to the manufacturer’s instructions and sequenced
using the primers indicated in Table 3. The sequences were
TABLE 3 | Oligos and primers used for CRISPR/Cas9 mediated geneome editing.
Primer Sequence
CYLD Guide top oligo CACCAGAGTGGAATCTGTTCTCGG
Guide bottom oligo AAACCCGAGAACAGATTCCACTCT
Forward Primer ACAAAGACTATCACGTATACGATACCCG
Reverse Primer TTAACTTCAGCCAATGAGCCCA
Sequencing Primer AGGAGCGAGAACACTGTT
IKKε Guide top oligo CACCGAGAAGTTCGTCTCGGTCTA
Guide bottom oligo AAACTAGACCGAGACGAACTTCTC
Forward Primer CACCCATCTTGGTTTCCTAGAGAA
Reverse Primer AGCCTCACCTTTTCCATCTTAGAGAAC
Sequencing Primer ATGGCTCTGTCAGCCCAT
TBK1 Guide top oligo CACCCATAAGCTTCCTTCGTCCAG
Guide bottom oligo AAACCTGGACGAAGGAAGCTTATG
Forward Primer GATGATTTTGCTTTTGATACTATTATGGC
Reverse Primer GGTTGTACAAACCCTAATTTTCAACAGT
Sequencing Primer TATCCATTTCTGAATTCC
analyzed using the Tracking of Indels by DEcomposition (TIDE)
software (Brinkman et al., 2014).
RESULTS
IKKε and TBK1 Are Activated Upon T Cell
Activation and Can Directly Phosphorylate
CYLD at Ser418
IKKε and its homolog TBK1 were previously shown to be
activated upon crosslinking of CD3 and the co-stimulatory
receptor CD28 (Yu et al., 2015). In agreement, we found that
treatment of the Jurkat T cell line with a combination of
phorbol myristate acetate (PMA) and Ionomycin (I), which
mimics TCR signaling by activating PKC and calcium influx,
results in the activation of IKKε and TBK1 as assessed by
immunoblotting with an antibody that specifically recognizes
Ser172 phosphorylation in the IKKε/TBK1 activation loop
(Kishore et al., 2002). Similar results were obtained in primary
murine CD4+ T cells (Figure 1). We next investigated if CYLD
can be phosphorylated by IKKε or TBK1 in the context of
TCR signaling. We focused on CYLD phosphorylation at Ser418,
which can be easily assessed using a phospho(Ser418)-CYLD-
specific antibody. Stimulation of Jurkat T cells with anti-
CD3/CD28 or PMA/I led to the rapid phosphorylation of CYLD
at Ser418 (Figure 2A). The faster migrating band in the case of
immunoblotting for total CYLD corresponds to the previously
reported CYLD cleavage product generated by MALT1 (Staal
et al., 2011). Although TNF was previously shown to trigger
CYLD phosphorylation in Jurkat, HeLa, or HEK 293 cells,
leading to the appearance of a slower migrating form of CYLD
(Reiley et al., 2005), stimulation of our Jurkat T cells with
TNF did not lead to a band shift or detection of a band
with the phospho(Ser418)-specific antibody, suggesting either
no phosphorylation or phosphorylation at other sites. It should
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FIGURE 1 | The noncanonical kinases IKKε and TBK1 are activated upon TCR
stimulation. Jurkat T cells (A) or primary mouse CD4+ T cells (B) were
stimulated with 200 ng/ml PMA and 1µM Ionomycin for the indicated times.
Protein levels were determined by immunoblotting. Activation of IKKε and
TBK1 was determined using an antibody specifically recognizing their
phosphorylation at Ser172. Results shown are representative for three (A) and
two (B) independent experiments.
be noted however, that a phospho-CYLD specific signal was
detected in several other Jurkat cell clones tested (Figure S1),
indicating clonal differences. The TCR- and PMA/I-induced
Ser418 phosphorylation of CYLD could be completely prevented
by dual inhibition of IKKε and TBK1, usingMRT67307, while the
IKKβ inhibitor TPCA1 had no effect (Figure 2B). CYLD Ser418
phosphorylation was also observed upon co-expression with
IKKε or TBK1, but not upon co-expression of their catalytically
inactive counterparts (K38A) in HEK 293T cells (Figure 2C).
When the Ser418 residue in CYLD was mutated to alanine, we
could no longer detect its IKKε/TBK1-mediated phosphorylation
using the phospho(Ser418)-CYLD-specific antibody, confirming
phosphorylation at Ser418. However, we still detected a band
shift using an antibody against the epitope-tag fused to CYLD,
indicating the presence of additional IKKε/TBK1-mediated
phosphorylation sites in CYLD upon overexpression of the
kinases. Further, in an in vitro kinase assay we could show
that recombinant IKKε and TBK1 can directly phosphorylate
CYLD at Ser418 (Figure 2D). Together these data suggest that
T cell activation is associated with the IKKε/TBK1 mediated
phosphorylation of CYLD at Ser418.
The IKKε/TBK1 Inhibitor MRT67307 Inhibits
CYLD Phosphorylation Independent of
IKKε and TBK1
As MRT67307 blocks both IKKε and TBK1, we wanted
to determine which of the two kinases is responsible for
CYLD phosphorylation. Therefore, we first tested PMA/I-
induced CYLD phosphorylation in primary CD4+ T cells
from IKKε deficient mice. As a control, wild-type and IKKε
deficient cells were stimulated in the presence of MRT67307.
MRT67307 significantly decreased CYLD phosphorylation in
wild-type cells (Figure 3A). However, there was no difference in
CYLD phosphorylation between wild-type and IKKε knockout
cells. Moreover, CYLD phosphorylation was still inhibited by
MRT67307 in IKKε deficient cells. Together, these results suggest
that TCR-induced CYLD phosphorylation is independent of
IKKε. Alternatively, the effect of IKKε deficiency may be
masked by the redundant function of TBK1. To further
investigate a possible redundancy between IKKε and TBK1,
we generated IKKε and TBK1 double deficient Jurkat T cells
using CRISPR/Cas9 technology. Several independent clones were
derived from single cells. Knockout of IKKε and TBK1 was
confirmed by immunoblotting as well as by genomic sequencing
of the region of interest. Unexpectedly, a phospho(Ser418)-
CYLD signal was still detectable upon PMA/I stimulation
in the IKKε/TBK1 double deficient Jurkat cells, indicating
that a kinase different from IKKε and TBK1 is responsible
for CYLD phosphorylation (Figure 3B). Furthermore, this
signal could be inhibited by pre-treatment with MRT67307,
suggesting that this inhibitor acts independently of IKKε/TBK1
(Figure 3C). As it was shown previously that MRT67307
can inhibit IKKε and TBK1 at concentrations as low as 1–
2µM (Clark et al., 2011a), the concentration of 10µM used
may have led to off-target effects. Therefore we tested if the
phospho(Ser418)-CYLD signal could also be inhibited when
using MRT67307 at lower concentrations (Figure 3D). Here we
could show that 5µM MRT67307 completely prevented CYLD
phosphorylation, while 1 or 2µM reduced the phospho(Ser418)-
CYLD signal only partially (Figure 3D). Taken together, these
results indicate that MRT67307 inhibits the phospho(Ser418)-
CYLD signal independent of its IKKε and TBK1 inhibitory
properties.
The phospho(Ser418)-CYLD-Specific
Antibody Detects a Protein Distinct From
CYLD
To further elucidate the importance of CYLD phosphorylation
at Ser418 for proximal TCR signal transduction, we generated
CYLD knockout cells by CRISPR/Cas9 to subsequently
reconstitute with CYLD(S418A) or CYLD(S418E) mutants that
prevent or mimic CYLD phosphorylation at Ser418, respectively.
Absence of CYLD was confirmed by immunoblotting as well as
genomic sequencing. Three different CYLD-deficient Jurkat T
cell clones were characterized for signaling in response to PMA/I.
While all clones show similar inducible IκBα phosphorylation,
they differ strongly in JNK activation (Figure 4A). JNK
phosphorylation in clone #10 is comparable to wild-type
Jurkat T cells, while clone #8 shows decreased and clone #9
increased JNK phosphorylation. This clonal variation between
the different CYLD deficient Jurkat T cell clones illustrates that
one should be highly cautious when using specific knockout
cell clones generated by CRISPR/Cas9 and that the effect
of CYLD reconstitution should be tested in order to make
valid conclusions on the impact of CYLD deficiency on JNK
activation. The latter was beyond the scope of the current study.
Most surprisingly, however, western blotting and detection with
the phospho(Ser418)-CYLD-specific antibody still revealed the
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FIGURE 2 | The deubiquitinase CYLD is phosphorylated at Ser418 by IKKε and TBK1. (A) CYLD phosphorylation at Ser418 is observed upon TCR- but not TNFR
stimulation. Jurkat T cells were stimulated with 200 ng/ml PMA and 1µM Ionomycin or 20µg/ml anti-CD3 and anti-CD28 or 1,000 U/ml TNF for the indicated times.
(B) CYLD phosphorylation is abolished by IKKε/TBK1, but not IKKβ inhibition Jurkat T cells were stimulated with 200 ng/ml PMA for the indicated times. Cells were
pre-incubated in the presence or absence of 10µM IKKε/TBK1 inhibitor MRT67307 or 5µM IKKα/β inhibitor TPCA1. (C) IKKε/TBK1 co-expression induced CYLD
phosphorylation. HEK 293T cells were transfected with the indicated expression constructs and harvested 24 h post transfection. (D) CYLD is phosphorylated by IKKε
and TBK1 in vitro. 250 ng recombinant His-CYLD was incubated with 35 or 70 ng GST-IKKε IKKε or 35, 70, or 140 ng TBK1 in an in vitro kinase assay (A–D) Protein
levels were determined by immunoblotting. Results shown are representative at least three independent experiments.
same PMA/I-inducible phospho(Ser418)-CYLD signal in all
CYLD-deficient cell clones (Figure 4A). These data indicate that
the phospho(Ser418)-CYLD-specific antibody detects a protein
distinct from CYLD, but with the same molecular weight of
approximately 110 kDa. The impact of this finding on our current
data and previously published results of others using the same
antibody will be discussed below. From Figure 2C it is obvious
that this antibody specifically recognizes CYLD phosphorylation
at Ser418 upon overexpression. At this point, it is not possible
to exclude that the unspecific 110 kDa band masks a specific
phospho-CYLD band in the Jurkat cell line. We therefore
performed an immunoprecipitation using the phospho(Ser418)-
CYLD-specific antibody, followed by western blotting with a
CYLD antibody (Figures 4B,C). Indeed, CYLD could be readily
detected upon immunoprecipitation with the phospho(Ser418)-
CYLD-specific antibody from PMA/I-stimulated Jurkat T cells
and primary murine CD4+ T cells, showing that CYLD is
indeed phosphorylated at Ser418 upon T cell stimulation but
that its direct detection with the phospho(Ser418)-CYLD-
specific antibody in a western blot is masked by another
inducible protein of the same size that is recognized by the same
antibody.
To determine if the specific phosphorylation of CYLD is
dependent on IKKε and TBK1 as hypothesized earlier, we
performed an immunoprecipitation with the phospho(Ser418)-
CYLD-specific antibody in IKKε/TBK1 deficient cells
(Figure 5A). While we could detect immunoprecipitated
CYLD in PMA/I stimulated wild-type Jurkat T cells, we did
not detect any CYLD upon immunoprecipitation with the
phospho(Ser418)-CYLD-specific antibody in the IKKε/TBK1
knock-out cells, indicating that CYLD phosphorylation is indeed
dependent on these two kinases. Interestingly, we could detect
a band with the phospho(Ser418)-CYLD-specific antibody in
the total lysate control of the IKKε/TBK1 knock-out clones
(Figures 3B,C, 5A), indicating that this antibody specifically
detects phosphorylated CYLD under native conditions, while
it additionally detects an unknown protein of the same size in
denaturing conditions. We further confirmed the importance of
IKKε and TBK1 for CYLD phosphorylation by treatment of cells
with MRT67307, followed by immunoprecipitation of cell lysates
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FIGURE 3 | The TCR-induced phospho(Ser418)-specific band occurs independent of IKKε and TBK1 (A) Primary mouse CD4+ T cells from wild-type (wt) or IKKε
knockout (ko) mice were pre-incubated for 30min in the presence of absence of 10µM IKKε/TBK1 inhibitor MRT67307 and subsequently stimulated with 200 ng/ml
PMA and 1µM Ionomycin for the indicated times. Specific proteins were determined by immunoblotting with the indicated antibodies. (B) Wild-type (wt) or IKKε/TBK1
double deficient Jurkat T cell clones were stimulated with 200 ng/ml PMA and 1µM Ionomycin for 15min. Specific proteins were determined by immunoblotting with
the indicated antibodies. (C) Wt or IKKε/TBK1 double deficient Jurkat T cell clones were pre-incubated for 30min in the presence or absence of 10µM IKKε/TBK1
inhibitor MRT67307 and then stimulated with 200 ng/ml PMA and 1µM Ionomycin for 15min. Specific proteins were determined by immunoblotting with the indicated
antibodies. (D) Wt Jurkat cells were pre-incubated for 30min in the presence of 1, 2, 5, or 10µM IKKε/TBK1 inhibitor MRT67307 and then stimulated with 200 ng/ml
PMA and 1µM Ionomycin for 15min. Specific proteins were determined by immunoblotting with the indicated antibodies. The data are representative of at least two
independent experiments.
with the phospho(Ser418)-CYLD-specific antibody (Figure 5B).
Here we show that specific phosphorylation of CYLD upon
immunoprecipitation is already completely inhibited at 2µM
MRT67307 (Figure 5B, left panel), while 10µM MRT67307 is
necessary to completely prevent the phosphorylation band in
the total lysate (Figure 5B, right panel). Taken together these
data show that CYLD is phosphorylated upon TCR stimulation
and that this phosphorylation is dependent on IKKε and TBK1.
However, the CYLD phosphorylation band in total cell lysates
is masked by the phosphorylation of another protein of the
same size which is also detected by the phospho(Ser418)-CYLD-
specific antibody. Specific CYLD phosphorylation should thus
be studied by immunoprecipitation with this antibody followed
by CYLD detection via immunoblotting.
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FIGURE 4 | The phospho(Ser418)-CYLD specific antibody still detects a protein of the same size as CYLD in CYLD-deficient cells. (A) Wild-type (wt) or three different
CYLD knockout (ko) Jurkat T cell clones were stimulated with 200 ng/ml PMA and 1µM Ionomycin for the indicated times. (B) Jurkat cells or (C) primary murine
CD4+ T cells were stimulated with 200 ng/ml PMA and 1µM Ionomycin (PMA/I) for the indicated times. Cell extracts were subjected to immunoprecipitation using the
phospho(Ser418)-CYLD-specific antibody. Beads without antibody were used as negative control (nc). (A–C) Specific proteins were determined by immunoblotting
with the indicated antibodies.
DISCUSSION
In the present study we show that co-expression of CYLD
and IKKε/TBK1 in HEK293T cells, as well as incubation with
recombinant IKKε/TBK1, results in CYLD phosphorylation
that can be detected with a phospho(Ser418)-CYLD-specific
antibody upon immunoblotting. A similar signal, sensitive
to MRT67307, could be detected in TCR-stimulated Jurkat
cells. CYLD is known to be phosphorylated on a serine
cluster (amino acids 418-444) in an IKKβ/NEMO-dependent
manner in response to TNF, LPS and PMA/I, resulting in
a band shift upon immunoblotting (Reiley et al., 2005). It
must be noted that we did not observe such a band shift
of CYLD upon TCR crosslinking or PMA/I stimulation of
Jurkat T cells, while we did detect a clear signal using the
phospho(Ser418)-CYLD antibody. At the functional level, CYLD
phosphorylation was previously shown to prevent CYLD-
mediated TRAF2 deubiquitination and to promote TNF-induced
gene expression (Reiley et al., 2005). Similarly, CYLD Ser418
phosphorylation upon co-expression of IKKε was found to
decrease its DUB activity (Hutti et al., 2009). IKKε-dependent
CYLD Ser418 phosphorylation and inactivation of its DUB
activity has also been reported in response to stimulation of the
C-type lectin receptor DC-SIGN in dendritic cells (Gringhuis
et al., 2014). Remarkably, there is also a contradictory report
showing that CYLD Ser418 phosphorylation increases its in
vitro DUB activity toward K63-linked polyubiquitin (Thein
et al., 2014). Surprisingly, using CYLD deficient cells we
found that the phospho(Ser418)-CYLD antibody cross-reacts
with another unknown protein of the same size as CYLD,
and whose phosphorylation is also inhibited by MRT67307.
These findings not only forced us to reevaluate our findings
on TCR-induced CYLD phosphorylation, they also imply
that one should be very cautious with the interpretation of
several published findings using the phospho(Ser418)-CYLD
antibody (Table 4). However, by immunoprecipitation with the
phospho(Ser418)-CYLD-specific antibody followed by CYLD
detection via immunoblotting and detection with anti-CYLD,
we were able to detect specific CYLD phosphorylation, and
could show that this was indeed dependent on IKKε and TBK1,
confirming our initial hypothesis.
Antibodies are among the most frequently used research tools
in basic science and are used in a wide range of applications.
Many antibodies are however not properly validated. One of the
pitfalls is that detection of a single band of the correct molecular
weight on a western blot is often used to demonstrate specificity.
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FIGURE 5 | CYLD is phosphorylated in an IKKε/TBK1 dependent manner, which can be detected by immunoprecipitation of CYLD using the
phospho(Ser418)-CYLD-specific antibody. (A) Wild-type (wt) or IKKε/TBK1 double knockout (ko) Jurkat T cell clones were stimulated with 200 ng/ml PMA and 1µM
Ionomycin (PMA/I) for 30min. (B) Wt Jurkat T cells were pre-incubated for 30min in the presence of 2 or 10µM IKKε/TBK1 inhibitor MRT67307 and then stimulated
with 200 ng/ml PMA and 1µM Ionomycin for 30min. (A,B) Cell extracts were subjected to immunoprecipitation using the phospho(Ser418)-CYLD-specific antibody.
Beads without antibody were used as negative control (nc). Specific proteins were determined by immunoblotting with the indicated antibodies.
TABLE 4 | Publications related to CYLD phosphorylation on Ser418.
References Kinase Context Effect
Beli et al., 2012 nd TNF, ionizing radiation or etoposide treatment of U2OS cells nd
Gringhuis et al., 2014 IKKε DC-SIGN stimulation of dendritic cells Reduced DUB activity; reduced Bcl3 deubiquitination
and nuclear translocation
Thein et al., 2014 IKKα/β Postsynaptic density Increased DUB activity
Zhu et al., 2014 IKKε/TBK1 Co-expression with TBK1 or IKKε in HEK 293 cells, abrogated by
MRT67307 treatment
nd
nd, not determined.
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TABLE 5 | Publications in which MRT67307 was used.
References Intended
target
Other
targets
IC50
[nM]
Effect of inhibitor treatment Confirmation of
inhibitor effects
Concentration
Clark et al., 2011a TBK1/IKKε 19/160 Inhibition of PolyI:C induced IRF3 phosphorylation, but not
JNK and p38 phosphorylation and reduced LPS-induced
IFNβ production in macrophages; Enhanced NF-κB activation
in response to IL-1 or TNF and PolyI:C or LPS in MEF cells
and macrophages, respectively
2µM
Gleason et al., 2011 TBK1/IKKε Reduced OPTN phosphorylation in LPS-treated BMDMs in
combination with TAK1 inhibitor 5Z-7-oxozeanol.
Smith et al., 2011 TBK1/IKKε Inhibition of LPS-induced Pellino-1 induction and IRF3
phosphorylation in BMDMs; Reduced IKKε and TBK1
dependent Pellino 1 phosphorylation in vitro; Reduced LPS-
or PolyI:C-induced Pellino 1 activation in macrophages
2µM
Clark et al., 2011b TBK1/IKKε Increased TBK1 and IKKε activationin Pam3CSK4 stimulated
BMDMs
IKKε and TBK1
knockout MEF
cells
2µM
Dzamko et al., 2012 TBK1/IKKε Inhibition of phosphorylation of LRRK2 in Pam3CSK4
stimulated RAW 264.7 cells
2µM
Liu et al., 2012 TBK1 Abrogation of thapsigargin-dependent IRF3 phosphorylation
in MEF cells
2µM
Bruni et al., 2013 TBK1/IKKε Reduced ERK phosphorylation in response to PolyI:C in
BMDMs
IKKε and TBK1
knockout BMDMs
2µM
Jiang et al., 2015 TBK1/IKKε Decreased IFN-λ1 mRNA expression in short
dsRNA-stimulated human monocyte-derived DCs
0.1–10µM
Zhu et al., 2014 TBK1/IKKε Impaired CYLD (Ser418) phosphorylation upon co-expression
with IKKε/TBK1 in HEK cells; decreased LPS-induced
expression of IFNβ1, CCL5 and IL-6 in RAW 264.7 cells;
impaired viability of KRAS-dependent A549 and HCC44 cells
genetic evidence
(Tbk1−/− MEFs),
independent
inhibitor (CYT387)
0.1–10µM
Lopez-Pelaez et al.,
2014
TBK1/IKKε Inhibition of in vitro phosphorylation of IRF5 by TBK1; no
effect on nuclear translocation of IRF5 upon CL097 (TLR7/8)
in RAW 264.7 cells
2µM
Awuh et al., 2015 TBK1 Decreased NF-κB and IRF-1 nuclear translocation in
response to M. avium infection in monocyte derived
macrophages; Increased M. avium growth
independent
inhibitor (BX795)
5µM
Pillai et al., 2015 TBK1 Inhibition of mitotic progression and formation of
multinucleate cells in H460 and HeLa cells
independent
inhibitor (BX795)
(knockdown in
additional
experiments)
2µM
Yu et al., 2015 TBK1 Inhibition of AKT degradation in anti-CD3/CD28 stimulated
CD4+ T cells in the presence of cycloheximide
2µM
Bruni et al., 2015 TBK1/IKKε Increased viral RNA production in pDCs infected with yellow
fever life vaccine and reduced type I IFN production
1µM
Saric et al., 2016 TBK1 No effect on LPS-induced lysosome tubulation in RAW 264.7
macrophages; inhibition of LPS-induced IRF3
phosphorylation
2µM
Heo et al., 2015 TBK1 Inhibition of recruitment of OPTN, NDP52 and SQSTM1 to
depolarized mitochondria in Antimycin A and Oligomycin A
treated HeLa cells
TBK1−/− cells 2µM
Swamy et al., 2015 TBK1/IKKε Reduced Ifnα and Ifnl mRNA induction, but no effect on Ifnγ
upregulation in CD3-stimulated intestinal intraepithelial
lymphocytes
1µM
Schweitzer et al.,
2016
TBK1/IKKε Marginal decrease in phosphorylation of IκBα and RelA
(Ser468) in the cytosol and RelA nuclear translocation in
TNF-stimulated HeLa cells
10µM
Achard et al., 2017 TBK1/IKKε Impaired IFNα production and TRAIL expression in response
to measles virus infection or R837 (TLR7 agonist) stimulation
in plasmacytoid DCs; Reduced TRAIL expression in response
to type I IFN
8µM
(Continued)
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TABLE 5 | Continued
References Intended
target
Other
targets
IC50
[nM]
Effect of inhibitor treatment Confirmation of
inhibitor effects
Concentration
Clark et al., 2012 SIK1 250 Increased TLR-induced expression of anti-inflammatory
cytokines (IL-10 and IL-1ra) in macrophages
Structurally
different inhibitors
(MRT199665,
HG-9-91-01,
KIN112), genetic
evidence
(LKB1−/−
macrophages)
2µM
SIK2 67
SIK3 430
MARK1-
4
27-52
NUAK1 230
MacKenzie et al.,
2013
SIK Increased LPS-induced IL-10 mRNA in BMDMs Independent
inhibitor (KIN112)
2µM
Petherick et al.,
2015
ULK1 45 Reduced amino acid starvation-induced ATG13
phosphorylation and autophagy in MEF cells
Structurally
different inhibitor
(MRT68921)
10µM
ULK2 38
Lazarus and Shokat,
2015
ULK1/2 Inhibition of autophagy (LC3 II accumulation) in HeLa cells Independent
inhibitor (BX795)
4µM
Draz et al., 2017 ULK1/2 Sensitization of LNCaP and C42B cells to cell death in the
presence of subtoxic concentrations of 3,3
′
-diindolylmethane
10µM
However, our results with a commonly used phospho(Ser418)-
CYLD antibody demonstrate this is far from true and that there
is a clear need for universal standards in antibody validation.
The International Working Group for Antibody Validation
(IWGAV) proposed a model with standard guidelines for
antibody validation based on five conceptual pillars or validation
strategies (Uhlen et al., 2015). First, the antibody should be
tested on cells in which expression of a protein of interest is
reduced or eliminated by RNA interference or knockout using
techniques such as CRISPR/Cas9. Second, orthogonal antibody-
independent methods such as mass spectrometry or qPCR can
validate expression. Third, protein expression can be compared
using two distinct antibodies that recognize non-overlapping
epitopes. Fourth, the expression of a protein that contains an
epitope-tag (e.g., Flag, His) can be analyzed in parallel using an
antibody raised against the target protein or an antibody raised
against the tag. Fifth, the protein can be affinity-purified with
the antibody and analyzed by mass spectrometry. Uhlen and
colleagues recommend using at least one of these pillars as a
minimal criterion for antibody specificity. However, our own
experience taught us that the parallel employment of several
strategies (overexpression, use of recombinant proteins and
knockout) is necessary for confident proof of antibody specificity.
A useful resource to select antibodies is the antibodypedia,
a repository of already validated antibodies which reports on
primary data, publications and commentaries on commercially
available antibodies (https://www.antibodypedia.com/).
Our observation that MRT67307 inhibits CYLD
phosphorylation in IKKε and TBK1 deficient cells indicates
a role for other MRT67307-sensitive kinases in TCR signaling.
While MRT67307 was first described as an inhibitor of TBK1
and IKKε (IC50 value of 19 and 160 nM, respectively) (Clark
et al., 2011a), several AMP-activated protein kinase (AMPK)-
related kinases were later described as additional targets:
MAP/microtubule affinity-regulating kinases (MARK1)-4 (IC50
value of 27–52 nM), NUAK family kinase 1 (NUAK1) (IC50
value of 230 nM), and the salt inducible kinases (SIK) (IC50 value
of 250, 67, and 430 nM for SIK1, SIK2, and SIK3, respectively)
(Clark et al., 2011a, 2012). Moreover, MRT67307 is also an
inhibitor of Unc-51 Like Autophagy Activating Kinase (ULK)
1 and ULK2 with IC50 values of 45 and 38 nM, respectively
(Petherick et al., 2015). In addition, the MRC PPU International
Centre for Kinase Profiling reported in vitro specificity screens
for several inhibitors (http://www.kinase-screen.mrc.ac.uk/
kinase-inhibitors), showing that MRT67307 not only inhibits
IKKε/TBK1 and the AMPK-related kinases MARK, MELK and
NUAK, but also Mixed Lineage Kinase (MLK) 1 and MLK3,
Janus kinase (JAK) 2, and Ca(2+)/calmodulin-dependent
protein kinase kinase β (CamKKβ). It will be interesting to
further investigate if any of the above mentioned kinases is
responsible for the inducible phosphoprotein signal detected
by the phospho(Ser418)-CYLD-specific antibody. Moreover,
the non-specificity of MRT67307 also implies that numerous
studies using this compound as an IKKε/TBK1 inhibitor may
have to be revisited (summarized in Table 5). The above findings
illustrate the importance of validating small compound kinase
inhibitors for specificity. Much valuable information is publicly
available from selectivity profile data of commonly used kinase
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inhibitors screened against panels of kinases (Davies et al., 2000;
Bain et al., 2003, 2007; Fabian et al., 2005; Fedorov et al., 2007;
Bamborough et al., 2008; Karaman et al., 2008). Additional
information on kinase screens or kinome scans can be found
on http://www.kinase-screen.mrc.ac.uk/kinase-inhibitors or
http://lincs.hms.harvard.edu/kinomescan/, respectively. Also
specific recommendations on the most optimal inhibitor or
combinations of inhibitors to study a number of selected kinases
have been published (Davies et al., 2000; Bain et al., 2003, 2007).
For example, using at least two structurally different inhibitors or
cells expressing a drug resistant mutant of the kinase to validate
findings is much desired. We would also recommend using
genetic knockout or siRNA mediated knockdown of the specific
kinase to complement data obtained from inhibitor studies.
In conclusion, the present case study clearly illustrates several
pitfalls when using antibodies and small compound inhibitors.
There is a clear need for better validation of antibodies and
small compound inhibitors to make results more reliable and
reproducible. More specifically, some previously published data
making use of MRT67307 or phospho(Ser418)-CYLD specific
antibodies may have led to wrong conclusions or at least need
to be validated by independent approaches if not yet done so.
Finally, our results also reveal that TCR stimulation results in the
IKKε/TBK1-independent phosphorylation of an unknown 110
kDa protein, which can be inhibited by MRT67307, and which
masks the detection of phosphorylated CYLD upon western
blotting with a phospho(Ser418)-CYLD-specific antibody. The
identification of this phosphorylated protein as well as the
responsible kinase that is inhibited byMRT67307 will be the topic
of future studies.
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